Biological Information
Background Information:
The TIE family of receptor tyrosine kinases comprises two members, TIE1 and TIE2 (Angiopoietin 1 receptor, Tyrosine-protein kinase receptor TIE-2, Tyrosine-protein kinase receptor TEK, P140 TEK, Tunica internal endothelial cell kinase, CD202b antigen, EC 2.7.1.112 ). These receptors are expressed predominantly in endothelial cells and are essential for vessel formation where they are required for the later stages of angiogenesis and vessel maintenance. TIE2 has roles in control of microvessel sprouting, integrity, and maturation. Angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2) have been identified as ligands of TIE2 receptor, which may regulate endothelial cell proliferation, differentiation and guide the proper patterning of endothelial cells during blood vessel formation. Inhibitors of TIE2 may inhibit vascular healing and tumor angiogenesis. GenBank NM_000459. The recombinant protein contains the amino acid substitutions Q939H and Q940H (native protein coordinates) with respect to GenBank NM_000459, both of these are reported in GenBank BC035514.
Target Class:
Kinase
Family:
RTK
Sub Family:
Protein Tyrosine
Protein Name:
TIE2
Protein Aliases:
Endothelial tyrosine kinase|Tunica interna endothelial cell kinase|Tyrosine kinase with Ig and EGF homology domains-2|Tyrosine-protein kinase receptor TEK|Tyrosine-protein kinase receptor TIE-2|hTIE2|p140 TEK|CD antigen CD202b
Accession Number:
NM_000459.1
UniProt Number:
Q02763
Gene Name:
TEK
Gene ID:
7010
Gene Aliases:
TIE2|TIE-2|VMCM1|CD202b
Target Species:
Human
Usage
Product Type:
Enzymes
Application:
Drug Discovery & Development
Storage Conditions:
6 months at -70°C
Usage disclaimer:
These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.
Assay Information
Assay Type:
Enzymatic
Clinical Relevance
Therapeutic Area:
Oncology/Immuno-Oncology